- Home
- CCD vs EVMN Comparison
CCD vs EVMN Comparison
Compare CCD & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCD | EVMN |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.8M | 628.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CCD | EVMN |
|---|---|---|
| Price | $22.62 | $16.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $38.60 |
| AVG Volume (30 Days) | 96.1K | ★ 325.9K |
| Earning Date | 01-01-0001 | 02-07-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 160.00 |
| 52 Week Low | $16.93 | $13.89 |
| 52 Week High | $24.68 | $24.03 |
Technical Indicators
Market Signals| Indicator | CCD | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 68.63 | N/A |
| Support Level | $22.06 | N/A |
| Resistance Level | $21.95 | N/A |
| Average True Range (ATR) | 0.30 | 0.00 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 93.58 | 0.00 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.